DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Actinic Keratosis Market Insight, Epidemiology, and Market Forecast—2036.” This comprehensive report provides an in-depth understanding of Actinic Keratosis, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Actinic Keratosis Market
The market size for Actinic Keratosis in the 7MM is expected to increase significantly by 2036.
According to the American Academy of Dermatology Association (AAD) (2026), more than 40 million Americans are estimated to develop actinic keratoses each year.
According to the National Institute for Health and Care Excellence (NICE), over 23% of individuals in the UK aged 60 years and above have actinic keratosis.
According to secondary research, the crude prevalence of actinic keratosis in France is estimated at 4.0%, with slightly higher prevalence in men than in women.
According to secondary research, the standardized prevalence of actinic keratosis in Germany is 2.7%, increasing with age to 11.5% in individuals aged 60–70 years. Approximately 1.7 million cases are documented annually.
Actinic keratosis is more prevalent in men and older populations due to cumulative sun exposure, with an estimated prevalence of around 20% in the United States.
KLISYRI (tirbanibulin) by Almirall and AMELUZ (aminolevulinic acid hydrochloride) by Biofrontera are key marketed therapies for actinic keratosis.
The emerging Actinic Keratosis pipeline includes Tuvatexib (VDA-1102) by Vidac Pharma and RLS-1496 by Rubedo Life Sciences.
Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/actinic-keratosis-market
Key Factors Driving the Actinic Keratosis Market
The increasing incidence of chronic ultraviolet (UV) radiation exposure and aging populations are contributing significantly to the rising prevalence of actinic keratosis globally. Actinic keratoses are premalignant intra-epithelial skin lesions associated with chronic sun exposure and may progress to cutaneous squamous cell carcinoma if left untreated.
Growing awareness regarding early diagnosis and preventive dermatologic care is supporting higher treatment rates and encouraging the use of lesion-directed and field-directed therapies. Management strategies such as cryotherapy, photodynamic therapy, topical agents, chemical peels, and laser resurfacing are increasingly being utilized to minimize disease progression risk.
Advances in topical therapies and photodynamic treatment approaches are improving patient adherence and outcomes by offering shorter treatment durations and improved tolerability. Additionally, the development of novel targeted therapies with innovative mechanisms of action is expected to reshape the future treatment landscape.
Actinic Keratosis Competitive Landscape
Several therapies are currently available and under development for the management of Actinic Keratosis. KLISYRI (tirbanibulin) is a microtubule inhibitor indicated for topical field treatment of actinic keratosis of the face or scalp and offers a convenient 5-day treatment regimen. AMELUZ (aminolevulinic acid hydrochloride) is a photosensitizing agent used in combination with photodynamic therapy for selective destruction of atypical keratinocytes.
The emerging pipeline includes Tuvatexib (VDA-1102), an investigational topical therapy designed to selectively target abnormal keratinocytes while sparing healthy tissue through modulation of Hexokinase-2 activity. RLS-1496 is being developed as a selective GPX4 modulator targeting pathological senescent cells associated with chronic dermatologic conditions.
Discover more about therapies set to grab major Actinic Keratosis market share @ Actinic Keratosis Treatment Landscape
Recent Developments in the Actinic Keratosis Market
In February 2026, Vidac Pharma announced that the first patient had been successfully enrolled and dosed in its Phase IIb clinical study evaluating VDA-1102 for the treatment of highly proliferative lesions of actinic keratosis.
In September 2025, Vidac Pharma announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a new interventional study focused on advanced actinic keratosis lesions.
In September 2025, Rubedo Life Sciences announced that the US FDA cleared the Investigational New Drug (IND) application for a Phase Ib/IIa clinical study of RLS-1496 in patients with actinic keratosis.
In June 2024, Almirall announced that the US FDA approved its supplemental New Drug Application (sNDA) to expand the treatment area for KLISYRI to up to 100 cm² on the face or scalp.
In February 2024, the MHRA and the European Commission approved an extension of the marketing authorization for AMELUZ, allowing its use with artificial daylight photodynamic therapy for the treatment of actinic keratosis.
What is Actinic Keratosis?
Actinic keratosis, also known as solar keratosis or senile keratosis, is a premalignant skin condition caused by abnormal proliferation of keratinocytes due to chronic ultraviolet radiation exposure. These lesions typically appear as red, scaly papules or plaques on sun-exposed areas of the skin and may vary in size, texture, and pigmentation.
Although progression of a single lesion to cutaneous squamous cell carcinoma is relatively uncommon, the risk increases in patients with multiple lesions. Early detection, treatment, and long-term monitoring are important components of disease management.
Actinic Keratosis Epidemiology Segmentation
The Actinic Keratosis epidemiology section provides insights into the historical and current Actinic Keratosis patient pool and forecasted trends for the seven major markets. The Actinic Keratosis market report proffers epidemiological analysis for the study period 2022–2036 segmented into:
Total Incident Cases of Actinic Keratosis in the 7MM
Total Prevalent Cases of Actinic Keratosis in the 7MM
Total Diagnosed Prevalent Cases of Actinic Keratosis in the 7MM
Gender-specific Cases of Actinic Keratosis in the 7MM
Age-specific Cases of Actinic Keratosis in the 7MM
Total Treated Cases of Actinic Keratosis in the 7MM
Scope of the Actinic Keratosis Market Report
Therapeutic Assessment: Actinic Keratosis current marketed and emerging therapies
Actinic Keratosis Market Dynamics: Key Market Forecast Assumptions of Emerging Actinic Keratosis Drugs and Market Outlook
Key Companies: Almirall, Biofrontera, Vidac Pharma, Rubedo Life Sciences, and others
Key Therapies: KLISYRI (tirbanibulin), AMELUZ (aminolevulinic acid hydrochloride), Tuvatexib (VDA-1102), RLS-1496, and others
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Actinic Keratosis Market Access and Reimbursement
To know more about Actinic Keratosis companies working in the treatment market, visit @ Actinic Keratosis Clinical Trials and Therapeutic Assessment
Table of Contents
Actinic Keratosis Market Overview at a Glance
Executive Summary
Key Events
Epidemiology and Market Methodology
Disease Background and Overview
Treatment and Management
Epidemiology and Patient Population
Marketed Drugs
Emerging Drugs
Actinic Keratosis Market Analysis
Key Opinion Leaders’ Views
Unmet Needs
SWOT Analysis
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: https://www.delveinsight.com/consulting/due-diligence-servicesCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
